论文部分内容阅读
从一间军队医院的药剂室到目前国内最大的滴丸剂型生产企业,天津天士力制药股份有限公司(股票代码:600535)已经发展成为资产总额14亿元的大型现代化制药企业。它以富有竞争力的创新机制聚集了海内外优秀的科研人员和管理人才,在全国制药业内创造了数项第一。随着其股票在上海证券交易所正式发行,天士力已经驶入了资本快车道,为二次创业、再度腾飞奠定了坚实的基础。作为只有8年历史的年轻企业,天士力制药股份有限公司董事长闫希军带领他的创业团队艰苦创业,为中国传统中药的现代化和国际化开创了一条成功之路。
From a pharmacy in a military hospital to the largest manufacturer of drip pills in China, Tianjin Tasly Pharmaceutical Co., Ltd. (stock code: 600535) has developed into a large-scale modern pharmaceutical enterprise with a total assets of 1.4 billion yuan. It has brought together outstanding scientists and managers both at home and abroad with its competitive and innovative mechanism and has created several firsts in the pharmaceutical industry across the country. With its shares officially issued on the Shanghai Stock Exchange, Tasly has entered the fast lane of capital and laid a solid foundation for its second start-up and its take-off. As an eight-year-old young company, Yan Xijun, chairman of Tasly Pharmaceutical Co., Ltd., led his entrepreneurial team to start his own business hard and created a successful path for the modernization and internationalization of traditional Chinese medicine.